Open Access. Powered by Scholars. Published by Universities.®

Women's Health Commons™

Open Access. Powered by Scholars. Published by Universities.®

Oncology

2008

Articles 1 - 2 of 2

Full-Text Articles in Women's Health

Physicians' Experiences With Brca1/2 Testing In Community Settings., Nancy L. Keating, Kathryn A. Stoeckert, Meredith M. Regan, Lisa Digianni, Judy E. Garber Dec 2008

Physicians' Experiences With Brca1/2 Testing In Community Settings., Nancy L. Keating, Kathryn A. Stoeckert, Meredith M. Regan, Lisa Digianni, Judy E. Garber

Kathryn Sabella

PURPOSE: We surveyed a national sample of nonacademic physicians who ordered BRCA1/2 testing to understand their implementation of genetic testing and to assess recommendations for surveillance and cancer risk management of women with positive test results.

PATIENTS AND METHODS: We surveyed physicians (N = 611 of 1,050; response rate, 58.2%) practicing in nonacademic settings who ordered BRCA1/2 testing during 2004 to 2005. We described physicians' experiences with testing and used multivariable regression models to identify factors associated with more complete counseling and with recommendations for cancer risk management for a BRCA1 mutation carrier.

RESULTS: Most physicians (68.2%) usually or always …

Go to article

Sensitization Of Ovarian Cancer Cells To Cisplatin By Genistein: The Role Of Nf-Kappab, Leigh A. Solomon, Shadan Ali, Sanjeev Banerjee, Adnan R. Munkarah, Robert T. Morris, Fazlul H. Sarkar Jan 2008

Sensitization Of Ovarian Cancer Cells To Cisplatin By Genistein: The Role Of Nf-Kappab, Leigh A. Solomon, Shadan Ali, Sanjeev Banerjee, Adnan R. Munkarah, Robert T. Morris, Fazlul H. Sarkar

Wayne State University Associated BioMed Central Scholarship

Abstract

Background

Platinum-resistance (PR) continues to be a major problem in the management of epithelial ovarian cancer (EOC). Response to various chemotherapeutic agents is poor in patients deemed PR. Genistein, a soy isoflavone has been shown to enhance the effect of chemotherapy in prostate and pancreatic cancer cells in vitro and in vivo by reversing chemo-resistance phenotype. The goal of this study was to investigate the effects of combination therapy with genistein and cisplatin as well as other cytotoxic conventional chemotherapeutic agents in platinum-sensitive (PS) and resistant EOC cells.

Methods

The PS human ovarian cancer cell line A2780 and its …

Go to article